Vaxinano Gains €6M for Nasal Vaccine Clinical Trials

LILLE, France, Oct. 29, 2024 - Vaxinano, a leading biotechnology firm focused on creating nasal vaccines for both preventive and therapeutic purposes, has successfully secured €6 million in a recent funding round. The investment was led by TCD Capital, Captech Santé, Nord France Amorçage (NFA), Wiseed, and several business angels, with additional contributions from BPI France. These funds will be used to advance Vaxinano's primary vaccines and immunotherapies into clinical trials, targeting diseases such as leishmaniasis, toxoplasmosis, and colibacillosis.

Utilizing its innovative Stellar-NP nanoparticle technology, Vaxinano is pioneering a new generation of nasal vaccines that are highly stable and free from adjuvants. These vaccines are designed to elicit strong and lasting immune responses against some of the most difficult pathogens, including various parasites, viruses, and bacteria. The platform has shown both preventive and therapeutic effectiveness across multiple species and a variety of infectious diseases. This breakthrough suggests a significant potential to transform the vaccine industry by enhancing safety, simplifying administration, and reducing costs—all crucial factors as infectious diseases continue to claim twenty million lives globally each year.

Jonathan Stauber, the CEO of Vaxinano, expressed his enthusiasm about the recent financial boost: "This funding round is a significant achievement for Vaxinano, allowing us to move our vaccine platform towards commercialization and prepare for clinical trials. We are excited to have the backing of such esteemed investors. The capital raised will facilitate the creation of a world-class leadership team and the progression of our promising vaccines, addressing critical medical needs." Didier Betbeder, the founder and Chief Scientific Officer, added: "The Stellar-NP technology has the potential to revolutionize the field of vaccines by offering more effective and economical solutions in the face of emerging pandemics."

Vaxinano, based in France, is dedicated to developing nasal vaccines to meet unfulfilled needs in the fight against infectious diseases. The company's groundbreaking platform, which does not require adjuvants, ensures high stability and global distribution capabilities. In just under three years, Vaxinano has created versatile mucosal vaccines that serve both preventive and therapeutic purposes. These vaccines target zoonotic diseases such as leishmaniasis, toxoplasmosis, and colibacillosis, aiming to protect humans, livestock, pets, and endangered species through its WildVax conservation program.